The Fatty Acid Synthase pipeline drugs market research report outlays comprehensive information on the Fatty Acid Synthase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Fatty Acid Synthase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Gastrointestinal, Infectious Disease, Oncology, and Metabolic Disorders which include the indications Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Tuberculosis, Respiratory Syncytial Virus (RSV) Infections, Breast Cancer, Colon Cancer, and Metabolic Disorders. It also reviews key players involved in Fatty Acid Synthase targeted therapeutics development with respective active and dormant or discontinued products.
The Fatty Acid Synthase pipeline targets constitutes close to nine molecules. Out of which, approximately six molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, and Preclinical stages are 1, and 5 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 2, and 1 molecule.
Fatty Acid Synthase overview
Fatty acid synthase (FASN) is a multifunctional enzyme that catalyzes the de novo biosynthesis of long-chain saturated fatty acids starting from acetyl-CoA and malonyl-CoA in the presence of NADPH. FASN consists of 7 catalytic activities and a site for the binding of the prosthetic group 4′-phosphopantetheine of the acyl carrier protein ([ACP]) domain.
For a complete picture of Fatty Acid Synthase’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
